232 related articles for article (PubMed ID: 15134039)
1. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
Halacová M; Průsa R; Kotaska K; Vávrová V
Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
Beringer PM; Vinks AA; Jelliffe RW; Shapiro BJ
Antimicrob Agents Chemother; 2000 Apr; 44(4):809-13. PubMed ID: 10722474
[TBL] [Abstract][Full Text] [Related]
3. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
5. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
Mouton JW; Punt N; Vinks AA
Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
[TBL] [Abstract][Full Text] [Related]
6. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
[TBL] [Abstract][Full Text] [Related]
7. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Zazo H; Martín-Suárez A; Lanao JM
Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
[TBL] [Abstract][Full Text] [Related]
9. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
[TBL] [Abstract][Full Text] [Related]
10. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
12. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen.
Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S
Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121
[TBL] [Abstract][Full Text] [Related]
13. Exploration of once-daily dosing of aminoglycosides through Bayesian simulation.
Garrelts JC
Pharmacotherapy; 1996; 16(2):286-94. PubMed ID: 8820474
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
Massie J; Cranswick N
J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
[TBL] [Abstract][Full Text] [Related]
16. Amikacin therapy of exacerbations of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Lau WK; Young LS; Osher AB; Dooley RR
Pediatrics; 1977 Sep; 60(3):372-7. PubMed ID: 408787
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]